Related Experiment Video
Updated: Sep 24, 2025

08:41
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
2.9K
S-217622, a 3CL Protease Inhibitor and Clinical Candidate for SARS-CoV-2
1School of Pharmacy, University of Otago, Dunedin 9054, New Zealand.
Journal of Medicinal Chemistry
|May 4, 2022
Abstract:
The coronavirus disease (COVID-19) pandemic has highlighted the ability of scientists to quickly react to the immense challenge presented to the world. The orally available 3CL protease inhibitor S-217622 is currently progressing through clinical trials and its discovery via structure-based drug design, screening and optimization by Shionogi and Hokkaido University is presented here.

